Unraveling the gene expression networks governing cancer initiation and development is
essential while remains largely uncompleted. With the innovations in RNA-seq technologies …

Cancer initiation and proliferation is regulated by both epigenetic and genetic events with
epigenetic modifications being increasingly identified as important targets for cancer …

DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …

Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …

Patients with advanced melanoma that is of low tumor‐associated antigen (TAA) expression
often respond poorly to PD‐1/PD‐L1 blockade therapy. Epigenetic modulators, such as …

In the past few years, it has become clear that mutations in epigenetic regulatory genes are
common in human cancers. Therapeutic strategies are now being developed to target …

Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic
options. The mechanisms underlying LMS development, including clinically actionable …

Infection of cervical epithelium with high-risk human papilloma virus (hrHPV) might result in
productive or transforming cervical intraepithelial neoplasia (CIN) lesions, the morphology of …

Epigenetic mechanisms comprising DNA methylation, histone modifications, and noncoding
RNAs affect chromatin structure and regulate gene expression. These mechanisms control …

S-Adenosyl-L-methionine (SAM) is a sulfonium molecule with a structural hybrid of
methionine and adenosine. As the second largest cofactor in the human body, its major …